22nd Annual Market Access Summit 2023 | 11 October 2023 | TBA, Toronto, ON

Secure your spot today to:
• Understand how Health Canada’s new National Strategy for Rare Diseases is unfolding.
• Gain valuable insight on how prepared Canada is for the new wave of treatments on the horizon.
• Discover how the increased substitution of biosimilars and the new generic agreement will impact the pharma marketplace.
• Realize the transformative impact that greater collaboration on gathering and sharing real-world evidence (RWE) is having on market access.
• Determine how Patient Support Programs (PSPs) need to evolve to ensure patients have access to the new treatments they require.

2023 Speakers

André Picard
Author and Journalist, Health Reporter and Columnist, The Globe and Mail

Daniel MacDonald
Director General, Drugs for Rare Diseases, Health Canada

Dr. Patricia Caetano
Executive Director, Provincial Drugs Program, Manitoba

Mitch Moneo
Assistant Deputy Minister, Pharmaceutical, Laboratory & Blood Services Division, British Columbia

Sylvie Bouchard
Director, Drug Evaluation and Technology Assessment for Reimbursement, Quebec

Brent Fraser
Vice-President, Pharmaceutical Reviews, Canada's Drug and Health Technology Agency

Ali Ghiassi
VP Industry Affairs & Government Relations, Logo

Ned Pojskic
Vice President, Pharmacy Benefits Management, Green Shield Canada

Jim Keon
President, CGPA

Dr. Stéphanie Michaud
President and Chief Executive Officer, BioCAn

Mo Amin
Vice President, Value, Access & Policy, AstraZeneca

Imran Ali
Director, Federal Policy & Provincial Affairs – Ontario & Atlantic, Logo

Sophie Rochon
Head of Access and Policy, Idorsia

Rosemarie Childerhose
Director of Market Access, Bausch Health

Ned Pojskic
VP, Pharmacy Benefits Management, Green Shield Canada

Chander Sehgal
Director, Market Access, Teva

Louise St-Onge
Lead, Market Access and Government Affairs Canada, Mitsubishi Tanabe Pharma Canada

Jody Engel, MScA
Country Manager Canada, Knight

Dr. Paul Moayyedi
Audrey Campbell Chair of Ulcerative Colitis Research, Assistant Dean of Research, Faculty of Health Sciences, McMaster University

Angelique Berg
Chief Executive Officer, CAPDM Driving

Tammy Moore
Chief Executive Officer, ALS SLA Canada

Linda Wilhelm
President, Canadian Arthritis Patient Alliance

Declan Hamill
Vice President, Legal, Regulatory Affairs and Compliance, Innovative Medicines Canada

Joe Farago
Executive Director, Private Payers and Investment, Innovative Medicines Canada

Kate Lee
Vice President, Research & Patient Programs, Crohn Colite Canada

Dr. Mina Tadrous
Assistant Professor, Leslie Dan Faculty of Pharmacy, and Investigator - Ontario Drug Policy Research Network, University of Toronto

Dr. Joel Lexchin
Professor, Institute of Health Policy, Management and Evaluation, University of Toronto

Paul Grootendorst
Associate Professor, Leslie Dan Faculty of Pharmacy, University of Toronto

Mark Smithyes
Former Chair, Current Director, Logo

2023 Partner

GOLD PARTNER:
• AmerisourceBergen

SILVER PARTNERS:
• PDCI Market Access
• Innovative Medicines Canada